Home / Specialty Pharmacy (page 30)

Specialty Pharmacy

European Commission Approves Novartis’ Jakavi for Treatment of Patients with a Rare Blood Cancer

Today, Novartis announced that the European Commission (EC) has approved Jakavi (ruxolitinib) for the treatment of patients with a rare blood cancer. The company said that the drug is now approved in Europe for the treatment of adults with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. …

Read More »

Imbruvica Demonstrates Promising Results in Phase III Trial in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Janssen Biotech, Inc. and partner Pharmacyclics, Inc. announced that an Independent Data Monitoring Committee determined that its late-stage trial, evaluating Imbruvica in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met its primary endpoint. According to the companies, during a pre-planned interim analysis of the Phase III …

Read More »

Valeant Raises its Offer to Acquire Salix

After Endo International offered a rival bid, Valeant Pharmaceuticals International announced that it has raised its offer for gastrointestinal drugmaker Salix Pharmaceuticals. The companies announced that they have entered into an amendment to their agreement and plan merger. Valeant has increased its offer price to acquire all the outstanding common …

Read More »

Bristol-Myers Squibb’s Resubmitted Application for its Hepatitis C Drug Accepted by the FDA

The US Food and Drug Administration (FDA) has accepted for review Bristol-Myers Squibb’s (BMS) resubmitted application for its investigational hepatitis C drug. The company said that the agency accepted its New Drug Application (NDA) for daclatasvir, an investigational NS5A replication complex inhibitor, for use in combination with Gilead’s sofosbuvir for …

Read More »

Baxter’s Investigational Hemophilia Drug Succeeds in Phase 3 Study

Today, Baxter International Inc. announced positive results from its late-stage trial evaluating its investigational treatment for patients with hemophilia A or B. The company said that its BAX 817, an investigational recombinant factor VIIa (rFVIIa), demonstrated positive safety and efficacy results in its Phase III clinical trial in patients with …

Read More »

FDNA to Launch Online Forum for the Genetics Expert Community

Pioneer in computer-aided dysmorphology analysis, FDNA, announced that it will launch an online forum for the genetics expert community for undiagnosed and challenging cases. The company said that it will unveil the “Unknown Forum” at the Annual Clinical Genetics Meeting ACMG 2015 in Salt Lake City, UT on March 26, …

Read More »

Study Finds An 80% Colorectal Cancer Screening Rate by 2018 Could Prevent 20,000 Deaths Per Year

Early detection of cancer is critical and can significantly improve survival for most cancer types. Therefore, it is important to utilize screening tools when available. A new study found that increasing colorectal cancer (CRC) screening rates to 80 percent by 2018 would prevent an additional 21,000 colorectal cancer deaths per …

Read More »

Neuralstem’s ALS Drug May be Effective for a Subset of Patients

Today, Neuralstem, Inc. announced top-line data from a mid-stage trial evaluating its investigational amyotrophic lateral sclerosis (ALS) treatment, saying that the drug met its primary safety endpoints. The company said that data from the Phase II trial of NSI-556 spinal cord-derived neural stem cells, under development for the treatment of …

Read More »

Genetic Test Maker 23andMe Hires Biotech Executive to Lead its Drug Development Effort

Google-backed genetic-testing company 23andMe is launching its own drug development unit, and bringing on former Genentech executive to become its chief scientist and lead the company’s research and development efforts. 23andMe has collected genetic information from more than 850,000 customers worldwide from its $99 DNA spit test and more than …

Read More »